ArticleSurgical endoscopy2025
Propensity score-matching analysis of retrograde artery first approach pancreatosplenectomy versus radical antegrade modular pancreatosplenectomy for 'shoulder' pancreatic cancers.
Article in Surgical endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
background'Shoulder' pancreatic cancer is a challenging situation owing to its close proximity to the branches of the celiac artery and portal vein (PV). A pioneering study demonstrated the feasibility of retrograde artery first approach pancreatosplenectomy (RAFAPS) in treating 'shoulder' pancreatic cancer. However, comparative studies on this topic are lacking.
methodsIn this single-centre cohort study, we retrospectively enrolled consecutive 'shoulder' pancreatic cancer cases from September 2019 to May 2023. Based on propensity score-matching analysis, we compared the safety and short-term oncological outcomes between RAFAPS and radical antegrade modular pancreatosplenectomy (RAMPS) for 'shoulder' pancreatic cancers. The primary outcome was a negative retroperitoneal margin rate.
resultsIn total, 135 (17.0%) 'shoulder' pancreatic cancers were identified among 794 pancreatic cancers during the study period. After matching based on body mass index, tumour size, distance from the right edge of the tumour to the left wall of the PV, and neoadjuvant chemotherapy, a cohort of 78 patients was selected for analysis (1:1 match, 39 per group). Invasion of splenic vein, splenic artery and PV were found in 40 (51.3%), 28 (35.9%) and 23 (29.5%) patients, respectively. RAFAPS was associated with a higher rate of negative retroperitoneal margins (100% vs 84.6%; relative risk = 1.18, 95% confidence interval [CI]: 1.034-1.351; P = 0.025) and less estimated blood loss (150 vs 300 ml; estimated difference: - 100 ml, 95% CI: - 200-0; P = 0.039) when compared to that of RAMPS.
conclusionRAFAPS is a safe and effective alternative to RAMPS for managing 'shoulder' pancreatic cancers in a minimally invasive era, with decreased blood loss and favourable retroperitoneal margin.
Indexed as
Identifiers
39904792What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.